Effect of Low-Dose Continuous Estrogen and Progesterone Therapy with Calcium and Vitamin D on Bone in Elderly Women
To the Editor: Recker and colleagues' relevant study reports on how continuous low-dose hormone replacement therapy (HRT) with adequate calcium and vitamin D intake provides a bonesparing effect in elderly women. The authors also found that no significant bone losses occurred in patients who received placebo plus calcium and vitamin D. The usefulness of bone mineral density measurements in the identification of persons with risk for bone fracture has recently been questioned (2) . Other studies have addressed the importance of resorptive markers, such as pyridinolones and N-telopeptide, as indicators of active resorption and risk for fracture and as indicators of treatment response. Recker and colleagues did not report on these measures, nor did they provide the fracture rate during the 3.5 years of the study.
Vitamin D has been found to decrease parathyroid hormonerelated bone resorption (3). In fact, low levels of vitamin D have been associated with acute fractures in postmenopausal women (4) . Thus, it would be interesting to investigate how calcium and vitamin D treatment modify pyridinolones and N-telopeptide values compared with HRT. Hormone replacement therapy is the cornerstone of prevention of postmenopausal osteoporosis. However, given the potential side effects of HRT, its use is still controversial for many patients. Alternative therapies could be offered to elderly patients if found to be effective in preventing bone resorption. To the Editor: Recker and colleagues (1) add to the body of knowledge on the bone-sparing efficacy and tolerability of lowdose estrogen and progesterone. We have two substantial concerns about aspects of the analysis and presentation of the data that detract from an otherwise well-done study. Figure 2 compares changes in the treatment and placebo groups. By presenting only one standard error of the mean with the effect measure, a reader may be led to believe that the differences are statistically significant. That is not the case. The authors have effectively presented a 68% confidence interval. Although we do not have access to the data, it is clear that many of those comparisons are not statistically significant at the more conservative 95% confidence intervals. Lang and Secic (2) have commented on this common occurrence in the medical literature. The authors state that before the study began, the minimal important difference in spinal and femoral bone mineral density between placebo and hormone replacement therapy would be 4.5% at the end of the 3.5 years. Neither site achieved this supposedly important threshold.
Francisco R. Lafita, MD, PhD
Our concern has nothing to do with the power of the study. It has to do with the "clinically" important difference. The reader is not given any correlation of percentage change with clinical outcomes. Are we to conclude that these differences are not important because they are less than the author's self-imposed minimally important difference? We invite their clarification. To the Editor: While preparing to present Recker and colleagues' article (1) for a journal club meeting, I noticed a discrepancy between the data presented in the Results section and the data reported in graphical form. The authors list differences between the HRT group and placebo group in terms of changes in bone mineral density and content at different sites. These changes are represented graphically in Figure 2 . While examining the data presented in graphical form, I was confused by the labeling of the lines that represent the two study groups. According to the key, the HRT group is represented by diamonds and the placebo group is represented by squares. However, upon comparing the graphs to the numerical data in the text, it is obvious that the key is reversed (that is, the HRT group is denoted by squares and the placebo group by diamonds). This led to much confusion because it appears that the author's results are the opposite of what they actually are.
This same discrepancy occurs a second time with the data presented on changes in biochemical markers between the two study groups. These data are graphically represented in Figure 3 . Again, the key states that diamonds denote the HRT group and squares denote the placebo group. In fact, the opposite is true. In response: Lafita and Garcia question the usefulness of dualenergy x-ray absorptiometry measurements of bone mineral density (BMD) in the identification of persons at risk for fracture. In point of fact, BMD is the most powerful measurable determinant of risk for fracture available today. The relative risk for fracture with each standard deviation reduction in BMD is 1.5 to 2.6 (1). Furthermore, as far as we know, antifracture efficacy has not been demonstrated for any agent in the absence of at least modest increases in BMD. Although resorption markers such as urinary pyridinolines and N-telopeptide are predictors of fracture, they are not as powerful as BMD itself (2, 3). We measured urinary hydroxyproline excretion in this study and found the expected changes in response to HRT. In our experience, urinary hydroxyproline measurement is as good as or better than the newer markers as an index of bone resorption. Its drawback is that it is technically difficult and time-consuming.
Jeffrey Brian Barnes
Lafita and Garcia indicate that alternatives to HRT should be considered for elderly persons because of potential side effects. We agree. Indeed, our results suggest that low-dose HRT combined with adequate calcium and vitamin D constitutes just such a reasonable alternative to conventional doses of HRT (because it results in fewer side effects). It is also much less expensive than many other alternatives.
Elasy and Levinsky present concerns about the data analysis and presentation. The data were analyzed by repeated-measures analysis of variance (SAS PROCedure MIXED [4] ). This analysis showed that the difference between the groups was highly statistically significant for all sites but the femoral neck. The fact that not all time points showed a significant difference between placebo and treatment is not germane. The sentence regarding the minimal important difference of 4.5% was inserted into the manuscript at the request of reviewers and the editor in response to their need to include the power and sample size calculations that were part of the original protocol. The 4.5% was not a criterion for clinical importance. It was the difference for which our sample size had an a priori 80% power, given assumptions about data dispersion. Even a 1% difference is clinically important for bone. Whether because of better than anticipated measurement precision or good luck, we demonstrated an improvement in BMD that was both statistically significant and clinically important.
Regarding clinical outcomes, reduction in fracture risk by increasing or maintaining BMD can take place without apparent improvement in clinical outcome (that is, improvement in the risk for fracture). Our study did not have power to detect antifracture efficacy.
We thank Barnes and Bess for pointing out the unfortunate error that occurred when the paper was prepared for printing. 
HFE Genotype in Patients with Hemochromatosis and Other Liver Diseases
To the Editor: Bacon and colleagues' report (1) indicates that determination of HFE genotype in patients with liver disease and possible iron overload may lead to identification of unsuspected C282Y homozygotes. In an editorial, Franks and Burke (2) note that some of the homozygotes did not have an elevated hepatic iron index; they suggest that the authors are guilty of circular reasoning because the authors conclude that absence of this criterion does not exclude the C282Y homozygous state. This is exactly what the data show, however, and the relevant question is whether this finding reflects a lack of full disease expression in these C282Y homozygotes.
Franks and Burke (2) also suggest that Bacon and colleagues should report on the degree of iron overload in patients with HFE mutations, as measured by quantitative phlebotomy. Although such data will be interesting, iron overload in these patients was already proven by quantitative liver iron determination (1). Finally, the editorial suggests that "To propose . . . that all patients with elevated transferrin saturation should undergo genetic testing is unwarranted" (2) , and that this recommendation should remain a matter for speculation until large population-based studies are completed. A closer examination of these apparently opposing points of view fails to reveal any substantial difference, however, because Bacon and colleagues stated that their algorithm should be validated in a larger series of patients before general clinical application. Franks and Burke make useful general recommendations for further investigations of the most accurate way to diagnose hemochromatosis and identify affected persons who are likely to develop complications of the disease and therefore require treatment. These recommendations are not necessarily relevant to Bacon and colleagues' report, however, and one hopes that readers will consult that informative article to draw their own conclusions.
Gordon D. McLaren, MD
University of California, Irvine Veterans Affairs Long Beach Healthcare System Long Beach, CA 90822
To the Editor: Franks and Burke (1) have chosen to raise complex issues of diagnostic criteria and population screening strategies in discussing an article that is really quite straightforward and informative to the practicing clinician. Bacon and colleagues (2) showed that the determination of HFE genotype is clinically useful in confirming HFE-associated hemochromatosis and in identifying otherwise unsuspected C282Y homozygotes in patients who have liver disease complicated by iron overload. The authors emphasized that their findings related to patients with liver disease and were not representative of iron overload in the general population. They further stated that "on a population basis, it remains to be determined how many C282Y homozygotes will never develop clinically significant iron overload."
Franks and Burke concluded that genetic testing for hemochromatosis is not warranted in patients with elevated serum transferrin saturation and that genetic testing should not form part of the "routine evaluation for hereditary hemochromatosis."
These conclusions are surprising in view of available data. First, the only causes of a significantly elevated serum transferrin saturation are iron overload and end-stage liver disease, in which transferrin synthesis is impaired. To submit such patients to genetic testing for hemochromatosis identifies those at high risk and avoids the controversial question of screening the general population. Second, it is established beyond doubt that iron overload per se is the cause of organ damage in hemochromatosis and related disorders (3, 4) and that its recognition and removal before tissue injury occurs prevents complications (4). Moreover, clinical manifestations and complications are directly related to the degree of iron overload (4) .
No one would deny the wisdom of, as Franks and Burke state, "gathering evidence and allow[ing] the evidence to guide practice." However, to delay implementing practical guidelines on the basis of established evidence hinders progress.
Lawrie W. Powell, MD, PhD
Royal Brisbane Hospital Brisbane, Queensland, Australia 4029
In response: We thank Dr. McLaren for his thoughtful comments about our paper, which clearly described the value of HFE genotyping in patients with liver disease and possible iron overload. We agree with Dr. McLaren that the accompanying editorial by Franks and Burke (1) did not address the issue that we had described-that is, how to differentiate patients with hemochromatosis from those with liver disease and secondary iron overload or those with liver disease and abnormal serum iron measures. We believe our data clearly show the utility of HFE genetic testing in all patients with liver disease who have abnormal iron metabolism measures in order to characterize whether they have HFE mutations that are associated with hemochromatosis. Again, we agree with McLaren that our proposed algorithm should be tested in a larger series of patients, and we have made no comments about the utility of this algorithm in populationbased screening. We hope the readers of our article will understand the significance of our findings in terms of evaluating patients with liver disease, a point that obviously was missed in the accompanying editorial.
Bruce R. Bacon In response: Because Bacon and colleagues (1) explored the utility of genetic testing, it is by definition circular to use the genetic test to discredit previously accepted diagnostic criteria for hemochromatosis in the absence of an independent gold standard. They found that some patients with liver disease who did not meet previously established criteria for hemochromatosis were homozygous for C282Y. The authors assumed that genotype should take precedence over the prior criteria, even though the predictive value of the various HFE genotypes has not yet been established. Indeed, given that C282Y homozygosity has been identified in patients with limited iron overload and no clinical manifestations (2), C282Y homozygosity in itself cannot be considered to be diagnostic. Furthermore, iron overload from hemochromatosis is known to exist in the absence of identifiable HFE mutations (3).
Nonetheless, we believe Bacon and colleagues may well be justified in arguing that the criteria for diagnosing hemochromatosis should be updated (for example, requiring a lower level of hepatic iron index or eliminating hepatic iron index as a criterion). This decision should be based on biological grounds, on better ways of quantifying iron overload, or on efficacy of treatment for patients who meet new criteria.
In reply to Dr. Powell, we agree that the use of tests for diagnosis of persons with illness differs greatly from the use of tests for screening healthy individuals. However, because genotype is not a perfect predictor of hemochromatosis, or its absence, we question use of genotype even in the routine evaluation of persons with iron overload. For example, in the circumstance of a person who otherwise meets criteria for hemochromatosis, a negative genetic test result is likely to prove more confusing than illuminating. Similarly, for patients with other identifiable causes of iron overload, genotyping is unlikely to be helpful unless the presentation is unusual.
Given the incomplete understanding of the genetic underpinnings of hemochromatosis, we believe it premature to use genotyping in routine clinical situations. Gathering information about the relation between phenotype and genotype, as Bacon and colleagues have done, is laudable and is essential to advancing knowledge so that genetic testing may someday become fully integrated into clinical practice.
Medical Uncertainty and Practice Variation
To the Editor: Dr. Daley's question "What should I do about hormone replacement?" (1) stems from an underlying assumption that hormone replacement is in itself a good thing. Such assumptions are used by philosophers who look at issues from a deontologic perspective. Deontologists believe that actions are good or bad in and of themselves. Lies are bad, no matter what the motive. Consequentialists are the traditional adversaries of deontologists. Consequentialists believe that an action's worth can be judged only by looking at the goodness of its outcomes.
If Dr. Daley approached her question from a consequentialist point of view, she would find the issues reframed. Instead of one question about the goodness of estrogen replacement, one asks the following: 1) Would it be good to treat my hot flashes? If so, how should I do it? 2) Would it be good to reduce my risk for cardiovascular disease? If so, how? 3) Would it be good to reduce my risk for osteoporosis? If so, how?
Now the issues become treatment decisions about single entities and comparisons of risk-benefit profiles of available therapies. Should I use nothing, estrogen, or clonidine for hot flashes? Should I use diet, statins, or estrogen for lipid treatment? Should I use exercise and calcium only, or should I add estrogen, alen-dronate, or calcitonin for osteoporosis? I believe that these questions are easier to answer because they first define the goal and then focus on the best specific therapy. But of course, as a dyed-in-the-wool consequentialist, I would see it that way. Deontologists and consequentialists would agree there is now too little information about Alzheimer prevention to put it on the agenda of women's health. Well, maybe some lesser deontologists would include it.
Jack Beaird, MD Woodlake Clinic Richfield, MN 55423
